Type 2 Diabetes Clinical Evidence and Research: What the Studies Show

Introduction

The evidence base for T2D treatment has expanded dramatically since 2016, driven primarily by GLP-1 receptor agonist and dual incretin agonist trials. The SUSTAIN program (10 trials of injectable semaglutide), PIONEER program (10 trials of oral semaglutide), and SURPASS program (5 major trials of tirzepatide) collectively enrolled over 40,000 patients and established a new standard of care. Combined with cardiovascular outcomes data from SELECT and SUSTAIN 6, kidney data from FLOW, and remission evidence from DiRECT, the case for GLP-1-based therapy as a central pillar of T2D treatment is now overwhelming.

This article walks through the major trials, their specific findings, and what they mean for treatment decisions.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey, and you can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Did the SUSTAIN Trial Program Show?

The SUSTAIN program tested injectable semaglutide (Ozempic®) across 10 randomized controlled trials in patients with T2D. Across the program, semaglutide 1.0 mg weekly reduced A1C by 1.4-1.8% from baseline and produced 4-7 kg of weight loss. Every trial showed semaglutide outperforming its comparator on both A1C and weight.

Quick Answer: The SUSTAIN, PIONEER, and SURPASS programs collectively enrolled over 40,000 patients testing incretin-based therapies.

SUSTAIN 1 (Sorli Et Al., 2017, Lancet Diabetes & Endocrinology)

Design: Semaglutide monotherapy (0.5 mg and 1.0 mg) vs. placebo in 388 treatment-naive T2D patients for 30 weeks.

Results:

• A1C reduction: -1.45% (0.5 mg), -1.55% (1.0 mg), -0.02% (placebo)
• Weight loss: -3.73 kg (0.5 mg), -4.53 kg (1.0 mg), -1.01 kg (placebo)
• A1C < 7% achieved: 74% (1.0 mg) vs. 25% (placebo)

Significance: Proved semaglutide worked as a standalone drug, without needing metformin as a backbone. The placebo group’s A1C barely moved, making the drug effect very clear.

SUSTAIN 2 (Ahren Et Al., 2017, Lancet Diabetes & Endocrinology)

Design: Semaglutide (0.5 mg and 1.0 mg) vs. sitagliptin 100 mg (a DPP-4 inhibitor) in 1,231 patients on metformin for 56 weeks.

Results:

• A1C reduction: -1.30% (0.5 mg), -1.64% (1.0 mg), -0.53% (sitagliptin)
• Weight loss: -4.3 kg (0.5 mg), -6.1 kg (1.0 mg), -1.9 kg (sitagliptin)

Significance: Semaglutide tripled the A1C reduction of sitagliptin and produced three times more weight loss. This trial was one of the clearest demonstrations that GLP-1 RAs are in a completely different league from DPP-4 inhibitors.

SUSTAIN 6 (Marso Et Al., 2016, New England Journal of Medicine)

Design: Cardiovascular outcomes trial. Semaglutide (0.5 mg and 1.0 mg) vs. placebo in 3,297 T2D patients with high cardiovascular risk for 104 weeks.

Results:

• Primary composite endpoint (CV death, nonfatal MI, nonfatal stroke): HR 0.74 (26% reduction, p<0.001 for noninferiority)
• Nonfatal stroke: HR 0.61 (39% reduction)
• Nonfatal MI: HR 0.74 (26% reduction)
• CV death: HR 0.98 (no significant difference)
• A1C reduction: -1.1% (0.5 mg), -1.4% (1.0 mg)
• Weight loss: -3.6 kg (0.5 mg), -4.9 kg (1.0 mg)

Significance: This was the trial that changed the guidelines. A diabetes drug that also prevents heart attacks and strokes by 26% isn’t just a glucose-lowering medication. It’s a cardiovascular drug that happens to lower glucose too. The FDA added a cardiovascular risk reduction indication to semaglutide’s label based on this data.

SUSTAIN 7 (Pratley Et Al., 2018, Lancet Diabetes & Endocrinology)

Design: Head-to-head vs. dulaglutide (Trulicity®) in 1,201 patients on metformin for 40 weeks. Compared semaglutide 0.5 mg vs. dulaglutide 0.75 mg, and semaglutide 1.0 mg vs. dulaglutide 1.5 mg.

Results:

• A1C reduction: semaglutide 1.0 mg achieved -1.8% vs. -1.4% for dulaglutide 1.5 mg
• Weight loss: semaglutide 1.0 mg achieved -6.5 kg vs. -3.0 kg for dulaglutide 1.5 mg

Significance: Established semaglutide as the most potent GLP-1 RA at the time, beating the then-market-leader dulaglutide at both dose levels on both endpoints.

SUSTAIN 10 (Capehorn Et Al., 2020, Diabetes & Metabolism)

Design: Semaglutide 1.0 mg vs. liraglutide 1.2 mg in 577 patients on 1-3 oral medications for 30 weeks.

Results:

• A1C reduction: -1.7% (semaglutide) vs. -1.0% (liraglutide)
• Weight loss: -5.8 kg (semaglutide) vs. -1.9 kg (liraglutide)

Significance: Once-weekly semaglutide decisively beat once-daily liraglutide, the previous gold standard GLP-1 RA. More effective and more convenient.

What Did the PIONEER Trials Find for Oral Semaglutide?

The PIONEER program tested oral semaglutide (Rybelsus®) in 10 trials. The 14 mg dose lowered A1C by 1.0-1.5% with weight loss of 3-5 kg. While less potent than injectable semaglutide, oral semaglutide matched or beat most other oral diabetes drugs and even matched injectable liraglutide.

PIONEER 1 (Aroda Et Al., 2019, Lancet)

Design: Oral semaglutide monotherapy (3 mg, 7 mg, 14 mg) vs. placebo in 703 treatment-naive patients for 26 weeks.

Results:

• A1C reduction: -0.6% (3 mg), -0.9% (7 mg), -1.2% (14 mg), -0.3% (placebo)
• Weight loss: -1.5 kg (3 mg), -2.3 kg (7 mg), -3.7 kg (14 mg)
• A1C < 7%: 72% (14 mg) vs. 31% (placebo)

PIONEER 2 (Rodbard Et Al., 2019, JAMA)

Design: Oral semaglutide 14 mg vs. empagliflozin 25 mg (an SGLT2 inhibitor) in 822 patients on metformin for 52 weeks.

Results:

• A1C reduction at week 26: -1.3% (oral semaglutide) vs. -0.9% (empagliflozin)
• At week 52, the difference narrowed slightly but oral semaglutide maintained superiority
• Weight loss was similar between groups (about 3.8 kg)

Significance: Oral semaglutide beat one of the best SGLT2 inhibitors for glucose control while matching it for weight loss.

PIONEER 4 (Rosenstock Et Al., 2019, JAMA)

Design: Oral semaglutide 14 mg vs. injectable liraglutide 1.8 mg vs. placebo in 711 patients for 52 weeks.

Results:

• A1C reduction: -1.2% (oral semaglutide), -1.1% (liraglutide), -0.2% (placebo)
• Weight loss: -4.4 kg (oral semaglutide), -3.1 kg (liraglutide), -0.5 kg (placebo)

Significance: An oral pill matched an injectable for glucose control and actually produced more weight loss. This was notable because oral bioavailability of semaglutide is only about 1%, meaning the tablet form achieves comparable effects despite dramatically lower absorption.

PIONEER 6 (Husain Et Al., 2019, New England Journal of Medicine)

Design: Cardiovascular safety trial. Oral semaglutide vs. placebo in 3,183 T2D patients at high cardiovascular risk for a median of 15.9 months.

Results:

• Primary composite endpoint: HR 0.79 (21% reduction, but not statistically significant as the trial was powered for noninferiority, not superiority)
• Cardiovascular death: HR 0.49 (51% reduction, nominally significant)
• All-cause mortality: HR 0.51 (49% reduction)

Significance: The cardiovascular death and all-cause mortality reductions were striking, though the trial wasn’t designed to prove superiority. The numbers were consistent with the cardiovascular benefits seen with injectable semaglutide in SUSTAIN 6, suggesting the oral form confers similar protection.

What Did the SURPASS Trials Show About Tirzepatide?

The SURPASS program tested tirzepatide (Mounjaro®) in 5 major phase 3 trials for T2D. Tirzepatide produced A1C reductions of 1.87-2.46% and weight loss of 7-13 kg, consistently outperforming all comparators including semaglutide. It demonstrated that dual GIP/GLP-1 agonism produces larger effects than GLP-1 agonism alone.

SURPASS-1 (Rosenstock Et Al., 2021, New England Journal of Medicine)

Design: Tirzepatide monotherapy (5 mg, 10 mg, 15 mg) vs. placebo in 478 treatment-naive patients for 40 weeks.

Results:

• A1C reduction: -1.87% (5 mg), -1.89% (10 mg), -2.07% (15 mg), -0.04% (placebo)
• Weight loss: -7.0 kg (5 mg), -7.8 kg (10 mg), -9.5 kg (15 mg)
• A1C < 5.7% (normal range): 31% (5 mg), 44% (10 mg), 52% (15 mg)
• A1C < 7%: 87% (5 mg), 92% (10 mg), 88% (15 mg)

Significance: Over half of patients on the 15 mg dose achieved a completely normal A1C. In treatment-naive patients, tirzepatide essentially normalized blood sugar for the majority.

SURPASS-2 (Frias Et Al., 2021, New England Journal of Medicine)

Design: Tirzepatide (5 mg, 10 mg, 15 mg) vs. semaglutide 1.0 mg in 1,879 patients on metformin for 40 weeks. This is the only large head-to-head trial between these two drugs.

Results:

Endpoint	Tirz 5 mg	Tirz 10 mg	Tirz 15 mg	Sema 1.0 mg
A1C reduction	-2.01%	-2.24%	-2.30%	-1.86%
Weight loss	-7.6 kg	-9.3 kg	-11.2 kg	-5.7 kg
A1C < 7%	82%	86%	86%	79%
A1C < 5.7%	27%	40%	46%	19%

All three tirzepatide doses were noninferior to semaglutide for A1C reduction. The 10 mg and 15 mg doses were statistically superior.

Significance: This is the most important trial in the SURPASS program. Tirzepatide decisively beat semaglutide, the most potent GLP-1 RA available. The A1C reductions at the 15 mg dose (2.30%) are the largest ever seen with any non-insulin diabetes medication. Weight loss was roughly double.

SURPASS-3 (Ludvik Et Al., 2021, JAMA)

Design: Tirzepatide (5 mg, 10 mg, 15 mg) vs. insulin degludec (titrated to target) in 1,444 patients on metformin for 52 weeks.

Results:

• A1C reduction: -1.93% (5 mg), -2.20% (10 mg), -2.37% (15 mg), -1.34% (insulin degludec)
• Weight change: -7.5 kg (5 mg), -10.7 kg (10 mg), -12.4 kg (15 mg), +2.3 kg (insulin degludec)

Significance: Tirzepatide produced better glucose control than titrated basal insulin while causing double-digit weight loss instead of weight gain. This trial directly challenges the long-held notion that insulin is the most powerful glucose-lowering tool. For patients who still produce some insulin, tirzepatide is more effective.

SURPASS-4 (Del Prato Et Al., 2021, Lancet)

Design: Tirzepatide (5 mg, 10 mg, 15 mg) vs. insulin glargine in 2,002 patients with T2D and high cardiovascular risk on 1-3 oral medications for 52 weeks.

Results:

• A1C reduction: -2.24% (tirzepatide 10 mg) vs. -1.44% (insulin glargine)
• Tirzepatide met its primary cardiovascular safety endpoint (MACE noninferiority)
• Weight loss: tirzepatide produced 7-12 kg loss while insulin caused 1.7 kg gain

SURPASS-5 (Dahl Et Al., 2022, JAMA)

Design: Tirzepatide (5 mg, 10 mg, 15 mg) vs. placebo, both added to insulin glargine, in 475 patients for 40 weeks.

Results:

• A1C reduction: -2.11% (tirzepatide 10 mg) vs. -0.93% (placebo)
• Tirzepatide added to insulin produced weight loss of 5.4-8.8 kg while placebo patients gained weight

Significance: Even when added on top of insulin, tirzepatide produced substantial additional A1C reduction and weight loss. This is relevant for patients already on insulin who aren’t at target.

What Did the SELECT and FLOW Cardiovascular and Kidney Trials Show?

The SELECT trial proved that semaglutide reduces cardiovascular events by 20% independently of diabetes, and the FLOW trial proved it protects kidneys in T2D patients with chronic kidney disease. These two trials, combined with SUSTAIN 6, establish GLP-1 RAs as cardiovascular and renal protective agents, not just glucose-lowering drugs.

SELECT (Lincoff Et Al., 2023, New England Journal of Medicine)

Design: Semaglutide 2.4 mg vs. placebo in 17,604 adults aged 45+ with established cardiovascular disease and BMI 27+, without diabetes, followed for a mean of 39.8 months.

Results:

• Primary endpoint (CV death, nonfatal MI, nonfatal stroke): HR 0.80 (20% reduction, p=0.002)
• All-cause mortality: HR 0.81 (19% reduction, nominally significant)
• Weight loss: -9.4% (semaglutide) vs. -0.88% (placebo)

Significance: SELECT was designed to test whether semaglutide’s cardiovascular benefits extend beyond what glucose-lowering provides. By excluding diabetes patients, the trial showed that the cardiovascular protection is at least partly independent of blood sugar improvement. The mechanism likely involves anti-inflammatory effects, reduction in visceral fat, improved endothelial function, and possibly direct effects on atherosclerotic plaques. For T2D patients, who get both the glucose-lowering AND the cardiovascular protection, the benefits are likely additive.

FLOW (Perkovic Et Al., 2024, New England Journal of Medicine)

Design: Semaglutide 1.0 mg vs. placebo in 3,533 patients with T2D and chronic kidney disease (eGFR 25-75 with UACR 100-5000) for a median of 3.4 years.

Results:

• Primary composite endpoint (kidney failure, 50% sustained eGFR decline, renal death, or CV death): HR 0.76 (24% reduction, p=0.0003)
• The trial was stopped early by the data monitoring committee because benefits were clear
• Kidney-specific composite (excluding CV death): HR 0.79 (21% reduction)
• CV death: HR 0.71 (29% reduction)

Significance: FLOW was the first dedicated kidney outcomes trial for a GLP-1 RA, and it succeeded definitively. About 1 in 3 people with T2D develop CKD, and kidney failure has devastating consequences. Semaglutide now joins SGLT2 inhibitors as a proven kidney-protective agent for T2D.

Key Takeaway: The UKPDS legacy effect proved early intensive glucose control reduces heart attacks for 10+ years afterward.

What Did the Landmark Legacy Trials Establish?

Before the GLP-1 era, two trials shaped everything we know about T2D treatment: the UKPDS and the DiRECT trial. The UKPDS proved that intensive glucose control prevents complications. DiRECT proved that T2D can be reversed through weight loss.

UKPDS (UK Prospective Diabetes Study, 1977-1997)

The UKPDS enrolled 5,102 newly diagnosed T2D patients in the UK and followed them for a median of 10 years, comparing intensive blood sugar control vs. conventional treatment.

Key findings from the main trial (1998, Lancet):

• Intensive control achieved A1C of 7.0% vs. 7.9% for conventional
• 25% reduction in microvascular complications (eye and kidney disease)
• 12% reduction in any diabetes-related endpoint
• The metformin sub-study (342 overweight patients): 42% reduction in diabetes-related death

The UKPDS Legacy Effect (Holman et al., 2008, New England Journal of Medicine): Ten years after the trial ended, the groups were re-examined. Despite A1C levels converging after the trial (both groups ended up around 8%), the intensive treatment group still had:

• 15% lower risk of MI (p=0.01)
• 13% lower all-cause mortality (p=0.007)
• Persistent reduction in microvascular complications

Significance: The legacy effect proved that early intensive glucose control has long-lasting cardiovascular benefits, even after the A1C advantage disappears. This “metabolic memory” concept argues strongly for treating T2D aggressively from the start.

DiRECT (Diabetes Remission Clinical Trial, Lean Et Al., 2018, Lancet)

Design: 298 T2D patients (diagnosed within 6 years, not on insulin) randomized to intensive weight management (total diet replacement at 825-853 kcal/day for 3-5 months, then food reintroduction) vs. standard care across 49 primary care practices in the UK.

Results at 12 months:

• 46% remission in intervention group vs. 4% in control
• Remission by weight loss: 86% (15+ kg), 57% (10-15 kg), 34% (5-10 kg), 7% (under 5 kg)
• Mean weight loss: 10 kg (intervention) vs. 1 kg (control)

Results at 24 months:

• 36% maintained remission (down from 46%)
• Weight regain was the main predictor of relapse

5-year follow-up (2024):

• 13% still in remission
• Those who maintained weight loss maintained remission

Significance: DiRECT proved that T2D is not inevitably permanent. Beta cells can recover function when the metabolic stress (excess liver and pancreatic fat) is removed. Roy Taylor’s personal fat threshold hypothesis explains why: each person has a threshold of body fat above which their beta cells fail. Getting below that threshold allows recovery. This reframed T2D from “progressive and irreversible” to “potentially reversible with sufficient weight loss.”

What’s in the Pipeline for T2D Treatment?

The pipeline includes higher-dose oral semaglutide, triple-receptor agonists like retatrutide, amycretin, and survodutide. Several of these compounds produce weight loss exceeding 20% while providing robust glucose control. The era of 15-25% weight loss from medications, which was unthinkable five years ago, is arriving.

Higher-dose Oral Semaglutide

Novo Nordisk has been testing oral semaglutide at 25 mg and 50 mg doses (compared to the current maximum of 14 mg). The PIONEER PLUS trial (2023) tested these higher doses and found:

• Oral semaglutide 50 mg lowered A1C by 2.0% (vs. 1.5% for 14 mg)
• Weight loss was 8.0 kg (50 mg) vs. 4.4 kg (14 mg) at 52 weeks

These higher doses narrow the gap between oral and injectable semaglutide, potentially making injections unnecessary for many patients.

Retatrutide (Eli Lilly)

Retatrutide is a triple agonist: GLP-1, GIP, and glucagon receptors. The phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine) tested it in people with obesity and showed:

• Up to 24.2% body weight loss at 48 weeks at the highest dose (12 mg)
• In a T2D subpopulation, A1C reductions were robust

By activating glucagon receptors (which increase energy expenditure) alongside the incretin pathways, retatrutide may produce even greater weight loss than tirzepatide. Phase 3 trials are underway.

Amycretin (Novo Nordisk)

Amycretin combines GLP-1 and amylin receptor agonism in a single molecule. Amylin is a hormone co-secreted with insulin that slows gastric emptying and reduces appetite through different brain pathways than GLP-1. A phase 1 trial reported by Novo Nordisk in late 2023 showed up to 13.1% weight loss after just 12 weeks, suggesting potentially faster onset and greater magnitude of effect.

Survodutide (Boehringer Ingelheim)

Survodutide is a dual GLP-1/glucagon receptor agonist. The phase 2 trial (Ambery et al., 2023) showed up to 18.7% weight loss at 46 weeks in people with obesity. The glucagon component increases hepatic fat oxidation, which is particularly relevant to T2D given the role of liver fat in the disease.

What the Aggregate Evidence Says

Looking across the entire body of evidence for GLP-1-based therapies in T2D, several conclusions are clear:

1. GLP-1 RAs and dual/triple agonists are the most effective pharmacological treatment for T2D when both glucose control and weight are considered.
2. Cardiovascular and kidney protection are real and clinically significant (20-26% reduction in MACE, 24% reduction in kidney disease progression).
3. The weight loss produced by newer agents approaches surgical levels without surgical risks.
4. For T2D patients with obesity (which is most of them), the case for GLP-1-based therapy as a first-line treatment is now stronger than the case for metformin alone.
5. The pipeline suggests things will only get better, with triple agonists potentially producing 20-25% weight loss alongside robust glucose control.

The main barriers remaining are cost and access. Until GLP-1 RAs are as affordable and widely available as metformin, treatment decisions will continue to be influenced by economics as much as evidence.

Bottom line: Pipeline drugs like retatrutide (triple agonist) produced up to 24.2% weight loss in phase 2 trials.

Myth vs. Fact: Setting the Record Straight

Misconceptions about treatment can delay good decisions. Here are three worth correcting before you make any choices about your care.

Myth: Type 2 diabetes is permanent and only gets worse. Fact: The DiRECT trial showed 46 percent of patients achieved diabetes remission at 12 months with structured weight loss. Remission is real, especially when caught early.

Myth: Insulin is the strongest diabetes medication. Fact: SURPASS-3 showed tirzepatide produced larger A1C reductions than insulin degludec, with weight loss instead of weight gain. GLP-1 receptor agonists have changed first-line treatment in the 2022 ADA/EASD consensus.

Myth: If your A1C is below 7, you don’t need to think about treatment changes. Fact: An A1C of 6.9 might mean you’re well-controlled, or it might mean your beta cells are quietly failing while you compensate. Cardiovascular and kidney protection from GLP-1s and SGLT2 inhibitors is now recommended regardless of A1C in many patients.

The Path Forward with TrimRx

Managing your metabolic health shouldn’t be a journey you take alone. The science behind GLP-1 medications offers a new level of hope for people facing type 2 diabetes and the related challenges that come with it. By addressing root hormonal and metabolic causes, these treatments provide a path toward more stable energy, better cardiovascular health, and improved quality of life.

At TrimRx, we’re committed to providing an empathetic and transparent experience. We understand the frustrations of traditional healthcare: the long waits, the unclear costs, and the lack of personalized care. Our platform is designed to put you back in control of your health. By combining clinical expertise with modern technology, we help you access the treatments you need while providing the 24/7 support you deserve.

Our program includes:

• Doctor consultations: professional guidance without the in-person waiting room
• Lab work coordination: baseline health markers monitored properly
• Ongoing support: 24/7 access to specialists for dosage changes and side effect management
• Reliable medication access: FDA-registered, inspected compounding pharmacies prepare Compounded Semaglutide or Compounded Tirzepatide when branded medications aren’t the right fit

Sustainable health is about more than a number on a scale or a single lab result. It’s about feeling empowered in your own body. Whether you’re starting to research your options or ready to take the next step with a free assessment, we’re here to guide you with science-backed, personalized care.

Bottom line: TrimRx provides a streamlined, medically supervised path to access the latest advancements in type 2 diabetes and weight management, all from the comfort of home.

FAQ

Which Clinical Trial Is Most Important for T2D Treatment Decisions?

SURPASS-2 is arguably the most practice-changing single trial because it directly compared the two most potent incretin-based drugs (tirzepatide vs. semaglutide) in T2D patients. It showed tirzepatide’s clear superiority for both A1C and weight. For cardiovascular risk decisions, SELECT (semaglutide) is the landmark trial. For kidney protection, FLOW is definitive.

Are There Long-term Safety Concerns with GLP-1 Medications?

Semaglutide’s longest-term data comes from SUSTAIN 6 (2 years) and the ongoing extensions of various trials. Injectable liraglutide (an older GLP-1 RA) has been on the market since 2010 with a good safety profile over 15+ years. The thyroid C-cell tumor signal from rodent studies has not materialized in human epidemiological data. Pancreatitis occurs at a rate of about 0.1-0.3%, consistent across trials. The most common side effects (GI) are manageable and typically improve over time.

How Do the SUSTAIN Trials Compare to the SURPASS Trials?

SURPASS generally showed superior results for tirzepatide compared to SUSTAIN’s semaglutide results. The head-to-head SURPASS-2 trial confirmed this: tirzepatide 15 mg lowered A1C 0.44% more than semaglutide 1 mg and produced about double the weight loss. However, SUSTAIN 6 and SELECT provide semaglutide with stronger cardiovascular outcomes data than tirzepatide currently has (tirzepatide’s dedicated cardiovascular trial, SURPASS-CVOT, is ongoing).

What Does the UKPDS Legacy Effect Mean for Treatment?

It means treating T2D aggressively from the start pays dividends for years, even decades, after. The UKPDS showed that patients who achieved better glucose control in the first 10 years had lower heart attack rates and lower mortality 10 years later, even after the A1C difference between groups disappeared. This argues against a “wait and see” approach and supports early use of effective medications.

Is There Evidence That GLP-1 RAs Should Be First-line Therapy Instead of Metformin?

No single trial has directly tested this question in a head-to-head, first-line design. The argument is built on indirect evidence: GLP-1 RAs produce larger A1C reductions, more weight loss, and have cardiovascular and kidney outcomes data that metformin lacks. The 2022 ADA/EASD consensus partially adopted this view by recommending GLP-1 RAs as first-line for T2D patients with obesity, cardiovascular disease, or CKD. For patients without these risk factors, metformin remains a reasonable first choice.

When Will Tirzepatide’s Cardiovascular Outcomes Trial Report?

The SURPASS-CVOT trial (comparing tirzepatide to dulaglutide for cardiovascular outcomes in T2D) is expected to report results in 2025-2026. If tirzepatide shows cardiovascular protection comparable to or better than semaglutide, it would further strengthen the case for dual incretin agonists as the preferred T2D treatment class. Given tirzepatide’s superior weight loss and glucose-lowering, many researchers expect positive cardiovascular results, but the data haven’t been published yet.

This article is for informational purposes only and does not constitute medical advice. Treatment decisions should be based on individual clinical circumstances in consultation with your healthcare provider.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.